Skip to main content

Table 4 Treatment-related AEs in all patients; N = 133

From: Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis

 

All AEs

Grade ≥ 3

n (%)

n (%)

Asthenia

48 (36.1)

13 (9.8)

Mucositis

35 (26.3)

6 (4.5)

Diarrhoea

33 (24.8)

4 (3.0)

Hand-foot skin reaction

20 (15.0)

1 (0.8)

Anorexia

16 (12.0)

2 (1.5)

Hyperglycaemia

13 (9.8)

1 (0.8)

Rash

12 (9.0)

3 (2.3)

Hypertension

12 (9.0)

1 (0.8)

Peripheral oedema

7 (5.3)

2 (1.5)

Thrombocytopenia

7 (5.3)

3 (2.3)

Anaemia

7 (5.3)

1 (0.8)

Pneumonitis

4 (3.0)

1 (0.8)

Cardiac toxicity

4 (3.0)

3 (2.3)

Hypercholesterolemia

4 (3.0)

0

Hypertriglyceridemia

4 (3.0)

0

Leucopoenia

4 (3.0)

1 (0.8)

Hepatic alterations

3 (2.3)

0

Hypothyroidism

3 (2.3)

0

Nausea

3 (2.3)

0

Vomiting

3 (2.3)

0

Abdominal pain

3 (2.3)

0

Weight loss

3 (2.3)

0

Headache

1 (0.8)

0

Epistaxis

1 (0.8)

0

Other

20 (15.0)

6 (4.5)

  1. AE = adverse event